• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Irene Kuter, DPhil, MD


  • Tan TC, Bouras S, Sawaya H, Sebag IA, Cohen V, Picard MH, Passeri J, Kuter I, Scherrer-Crosbie M.
    Time Trends of Left Ventricular Ejection Fraction and Myocardial Deformation Indices in a Cohort of Women with Breast Cancer Treated with Anthracyclines, Taxanes, and Trastuzumab.
    Journal Of The American Society Of Echocardiography : Official Publication Of The American Society Of Echocardiography. 2015 Mar 13.
  • Patani N, Dunbier AK, Anderson H, Ghazoui Z, Ribas R, Anderson E, Gao Q, A'Hern R, Mackay A, Lindemann J, Wellings R, Walker J, Kuter I, Martin LA, Dowsett M.
    Clin Cancer Res. 2014 Jun 10.
  • Ky B, Putt M, Sawaya H, French B, Januzzi JL, Sebag IA, Plana JC, Cohen V, Banchs J, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M.
    Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab.
    J Am Coll Cardiol. 2014 Mar 4;63(8):809-16.
  • Knudsen S, Jensen T, Hansen A, Mazin W, Lindemann J, Kuter I, Laing N, Anderson E.
    Development and validation of a gene expression score that predicts response to fulvestrant in breast cancer patients.
    PLoS ONE. 2014;9(2):e87415.
  • Boutrus RR, Abi Raad RF, Kuter I, Ancukiewicz M, Roberts L, Solomon N, Ngo T, Borick H, Ryan P, Moy B, Gadd M, Chien J, Younger J, Smith B, Taghian AG, Harris L.
    Circulating tumor cells as predictors of response and failure in breast cancer patients treated with preoperative chemotherapy.
    Int J Biol Markers. 2012 Sep 17:0.
  • Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, Cohen V, Banchs J, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M.
    Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab.
    Circ Cardiovasc Imaging. 2012 Sep 1;5(5):596-603.
  • Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Cohen V, Gosavi S, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M.
    Early Detection and Prediction of Cardiotoxicity in Chemotherapy-Treated Patients.
    Am J Cardiol. 2011 Mar 1.
  • Burstein HJ,Chen YH,Parker LM,Savoie J,Younger J,Kuter I,Ryan PD,Garber JE,Chen H,Campos SM,Shulman LN,Harris LN,Gelman R,Winer EP.
    VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy.
    Clin Cancer Res. 2008 Dec 1;14(23):7871-7.
  • Eichler AF, Kuter I, Ryan P, Schapira L, Younger J, Henson JW.
    Survival in patients with brain metastases from breast cancer: the importance of HER-2 status.
    Cancer. 2008 Jun;112(11):2359-67.
  • Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, Vogel CL, Goldstein LJ, Somlo G, Gradishar WJ, Hudis CA, Jahanzeb M, Stark A, Wolff AC, Press MF, Winer EP, Paik S, Ljung BM,.
    HER2 testing in breast cancer: NCCN Task Force report and recommendations.
    J Natl Compr Canc Netw. 2006 Jul;4 Suppl 3:S1-22; quiz S23-4. Review.
  • Burstein HJ, Bellon JR, Galper S, Lu HM, Kuter I, Taghian AG, Wong J, Gelman R, Bunnell CA, Parker LM, Garber JE, Winer EP, Harris JR, Powell SN.
    Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer.
    Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):496-504.
  • Yeh E, Slanetz P, Kopans DB, Rafferty E, Georgian-Smith D, Moy L, Halpern E, Moore R, Kuter I, Taghian A.
    Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer.
    AJR Am J Roentgenol. 2005 Mar;184(3):868-77.
  • Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E.
    Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.
    Cancer. 2003 Jun 15;97(12):2972-7.
  • Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, Parker LM, Ellisen LW, Kuter I, Gadd MA, Christian RL, Kennedy PR, Borges VF, Bunnell CA, Younger J, Smith BL, Winer EP.
    Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.
    J Clin Oncol. 2003 Jan 1;21(1):46-53.
  • Codington JF, Haavik S, Nikrui N, Kuter I, Vassileva C, Zhang H, Matson S, Chen X, Wu Z.
    Immunologic quantitation of the carcinoma specific human carcinoma antigen in clinical samples.
    Cancer. 2002 Feb 1;94(3):803-13.
  • Taghian AG, Assaad SI, Niemierko A, Kuter I, Younger J, Schoenthaler R, Roche M, Powell SN.
    Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel.
    J Natl Cancer Inst. 2001 Dec 5;93(23):1806-11.
  • Kuter I.
    Breast cancer.
    Oncologist. 2001;6(4):338-46.
  • Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP.
    Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.
    J Clin Oncol. 2001 May 15;19(10):2722-30.
  • Kuter I.
    Breast cancer update.
    Oncologist. 2000;5(4):285-92.
  • Kuter I.
    Breast cancer highlights.
    Oncologist. 1999;4(4):299-308.
  • Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T.
    Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.
    J Clin Oncol. 1999 Feb;17(2):485-93.
  • Kaufman JA, Crenshaw WB, Kuter I, Geller SC.
    Percutaneous placement of a central venous access device via an intercostal vein.
    AJR Am J Roentgenol. 1995 Feb;164(2):459-60.
  • Kuter I, Johnson-Wint B, Beaupre N, Gross J.
    Collagenase secretion accompanying changes in cell shape occurs only in the presence of a biologically active cytokine.
    J Cell Sci. 1989 Mar;92 ( Pt 3):473-85.